Aktienanalyse zu ADC Therapeutics SA (ADCT)ADCTADC Therapeutics SA

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ADC Therapeutics appears to be a good buy right now due to its recent price increase of 14.39% over the last five days and a current price of $1.14, which is significantly lower than the analyst price target of $5 to $8. The company's gross margin remains strong at 88.68%, indicating effective cost management despite ongoing losses. However, the main risk is the negative net income reported at -16,565,000 USD for Q2 2026, which highlights ongoing financial challenges that investors should monitor closely.